EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)

Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study)

Triple orale metronomische Chemotherapie versus Chemotherapie nach Ermessen des Arztes nach Versagen einer platinbasierten Therapie bei fortgeschrittenem Kopf-Hals-Krebs: Phase-III-randomisierte Studie (METRO-CHASE-Studie)

Akhil Kapoor iD, Anuj Gupta iD, Bipinesh Sansar iD, Bal Krishna Mishra iD, Pooja Gupta iD, Arpita Singh, Arvind Upadhyay, Lakhan Kashyap, Ankita Pal iD, Amit Kumar iD, Sambit S Nanda iD, Ashutosh Mukherji iD und 22 weitere

JCO Global Oncology · 2025-10 · (11)

DOI: 10.1200/go-25-00032 ↗

Auf einen Blick

Bei 214 Patient:innen mit fortgeschrittenem HNSCC nach platinbasierter Therapie verlängerte triple OMCT das Gesamtüberleben gegenüber CPD. Auch PFS, Lebensqualität und Verträglichkeit waren günstiger.

Fragestellung

Verbessert triple orale metronomische Chemotherapie das Gesamtüberleben im Vergleich zur Chemotherapie nach Ermessen des Arztes bei fortgeschrittenem HNSCC nach platinbasierter Therapie?

Methode

Phase-III-randomisierte, offene Studie mit 214 Patient:innen; 1:1-Zuteilung zu triple OMCT oder CPD. Primärer Endpunkt: OS; sekundär PFS, QOL und Sicherheit.

Ergebnisse

Medianes OS: 5 Monate vs. 3,1 Monate; HR 0,63 (95 %-KI 0,47–0,83; P = .00011). Medianes PFS: 4,8 vs. 2,7 Monate; HR 0,67 (95 %-KI 0,52–0,87; P < .0001). UAW Grad ≥3: 28,0 % vs. 39,3 % (P = .03).

Schlussfolgerung der Autor:innen

Triple OMCT ist laut Autor:innen eine wirksame und sichere Behandlung für fortgeschrittenes HNSCC nach platinbasierter Chemotherapie.

Kernaussagen

  • OS: 5 Monate unter triple OMCT vs. 3,1 Monate unter CPD
  • PFS: 4,8 Monate unter triple OMCT vs. 2,7 Monate unter CPD
  • Weniger UAW Grad ≥3 unter triple OMCT: 28,0 % vs. 39,3 %

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JCO Global Oncology, 2025-10. Verfasst von Akhil Kapoor und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha…. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Platinum-refractory advanced head and neck squamous cell carcinoma (HNSCC) has poor outcomes and limited treatment options, especially in resource-constrained settings. Triple oral metronomic chemotherapy (OMCT), involving low-dose continuous administration of chemotherapeutic agents, has shown promise in phase II studies but lacks evidence from randomized controlled trials. This study evaluated whether triple OMCT improves overall survival (OS) compared with chemotherapy of physician discretion (CPD). PATIENTS AND METHODS In this phase III randomized open-label study, 214 patients with advanced HNSCC who had previous platinum-based chemotherapy were randomly assigned 1:1 to receive either triple OMCT (arm A) with erlotinib, celecoxib, and methotrexate, or CPD (arm B). The primary end point was OS, with secondary end points including progression-free survival (PFS), quality of life (QOL), and safety. Kaplan-Meier and log-rank tests were used for OS and PFS, and Cox-proportional hazard models estimated hazard ratios. QOL was evaluated using European Organisation for Research and Treatment of Cancer QLQ-C30 and FACT H&N. RESULTS Median OS was 5 months in arm A and 3.1 months in arm B (hazard ratio [HR], 0.63 [95% CI, 0.47 to 0.83]; P = .00011). Median PFS was 4.8 months in arm A and 2.7 months in arm B (HR, 0.67 [95% CI, 0.52 to 0.87]; P < .0001). Previous treatment was a significant prognostic factor for OS, while age, tumor site, and previous treatment were significant for PFS. Triple OMCT improved global health status, physical functions, fatigue, and insomnia. It was well tolerated, with fewer grade 3 or higher adverse events than CPD (28.0% v 39.3%, P = .03). CONCLUSION Triple OMCT is an effective and safe treatment for advanced HNSCC after platinum-based chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsSquamous Cell Carcinoma of Head and NeckHumansMaleFemaleMiddle AgedAdministration, MetronomicAgedAdultAdministration, OralQuality of LifeMethotrexateCelecoxib

Substanzen

MethotrexateCelecoxib

Autor:innen und Institutionen

  • Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
  • Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
  • Department of Medical Oncology, Homi Bhabha Cancer Hospital & Research Centre, Muzaffarpur, India.
  • Department of Radiation Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
  • Department of Surgical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.
  • Department of Pathology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, India.

ORCID-Profile: Akhil Kapoor, Anuj Gupta, Bipinesh Sansar, Bal Krishna Mishra, Pooja Gupta, Ankita Pal, Amit Kumar, Sambit S Nanda, Ashutosh Mukherji, Ankita Rungta Kapoor, Aseem Mishra, Zachariah Chowdhury, Shashikant Patne, Neha Singh, Shreya Shukla, Satyendra Narayan Singh, Varun Shukla, M V Manikandan, Shripad Banavali, Somnath Dey, Kunal Ranjan Vinayak, Praveen Lakshman, Lokendra Gupta, Vijay Patil, Vanita Noronha, Kumar Prabhash

Zitieren

APA

Kapoor, A., Gupta, A., Sansar, B., Mishra, B. K., Gupta, P., Singh, A., Upadhyay, A., Kashyap, L., Pal, A., Kumar, A., Nanda, S. S., Mukherji, A., Kapoor, A. R., Pradhan, S., Mishra, A., Chowdhury, Z., Patne, S., Dhal, I., Singh, N., …, & Prabhash, K. (2025). Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study). JCO Global Oncology. https://doi.org/10.1200/go-25-00032

Vancouver

Kapoor A, Gupta A, Sansar B, Mishra BK, Gupta P, Singh A, et al. Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study). JCO Global Oncology. 2025. doi:10.1200/go-25-00032

BibTeX
@article{Kapoor2025,
  author = {Kapoor, Akhil and Gupta, Anuj and Sansar, Bipinesh and Mishra, Bal Krishna and Gupta, Pooja and Singh, Arpita and Upadhyay, Arvind and Kashyap, Lakhan and Pal, Ankita and Kumar, Amit and Nanda, Sambit S and Mukherji, Ashutosh and Kapoor, Ankita Rungta and Pradhan, Satyajit and Mishra, Aseem and Chowdhury, Zachariah and Patne, Shashikant and Dhal, Ipsita and Singh, Neha and Shukla, Shreya and Singh, Satyendra Narayan and Shukla, Varun and Manikandan, M V and Suresh, Arvind and Banavali, Shripad and Dey, Somnath and Vinayak, Kunal Ranjan and Lakshman, Praveen and Gupta, Lokendra and Gavel, Pratibha and Bandekar, Bhavesh P and Patil, Vijay and Noronha, Vanita and Prabhash, Kumar},
  title = {Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study)},
  journal = {JCO Global Oncology},
  year = {2025},
  number = {11},
  doi = {10.1200/go-25-00032}
}
Kostenlos starten →